---
title: "BlackRock Tech and Private Equity Term Trust | 10-Q: FY2025 Q1 EPS: USD -0.15"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/239197839.md"
datetime: "2025-05-07T20:33:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/239197839.md)
  - [en](https://longbridge.com/en/news/239197839.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/239197839.md)
generator: "portal-rs"
---

# BlackRock Tech and Private Equity Term Trust | 10-Q: FY2025 Q1 EPS: USD -0.15

EPS: As of FY2025 Q1, the actual value is USD -0.15.

### Segment Revenue

-   No revenue was recognized for the three months ended March 31, 2025, compared to $47,000 for the same period in 2024, due to the assignment of a customer contract to Factor Bioscience.

### Operational Metrics

-   **Net Loss**: The net loss for the three months ended March 31, 2025, was $8.2 million, compared to $6.6 million for the same period in 2024.
-   **Operating Expenses**: Total operating expenses decreased to $2.7 million for the three months ended March 31, 2025, from $5.8 million in the same period in 2024.
-   **Research and Development Expenses**: Decreased to $1.3 million for the three months ended March 31, 2025, from $1.5 million in the same period in 2024.
-   **General and Administrative Expenses**: Decreased to $1.4 million for the three months ended March 31, 2025, from $4.3 million in the same period in 2024.

### Cash Flow

-   **Operating Cash Flow**: Net cash used in operating activities was $2.1 million for the three months ended March 31, 2025, compared to $3.7 million for the same period in 2024.
-   **Free Cash Flow**: Not explicitly stated, but the net increase in cash and cash equivalents was $189,000 for the three months ended March 31, 2025.

### Unique Metrics

-   **Forward Sales Contract Expense**: Recognized a $5.3 million loss related to a forward sales contract entered into on March 31, 2025.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to complete IND enabling studies and submit an IND for ERNA-101 by 2026, with a Phase I clinical trial expected in the second half of 2026.
-   **Non-Core Business**: Actively seeking strategic partnerships to co-develop or out-license therapeutic assets.

### Related Stocks

- [BTX.US](https://longbridge.com/en/quote/BTX.US.md)

## Related News & Research

- [BlackRock Tchnlgy nd Prvt Eqty Trm Trst (NYSE:BTX) to Issue $0.05 Monthly Dividend](https://longbridge.com/en/news/278763468.md)
- [Nvidia Just Delivered Bad News for AMD and Intel](https://longbridge.com/en/news/297432140.md)
- [Caisse de depot et placement du Quebec Takes $8.90 Million Position in Albemarle Corporation $ALB](https://longbridge.com/en/news/297418340.md)
- [Equitable Holdings Inc. Takes Position in TechnipFMC plc $FTI](https://longbridge.com/en/news/297418121.md)
- [Richtech Robotics Inc. $RR Shares Bought by Bank of America Corp DE](https://longbridge.com/en/news/297416593.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**